Clicky

Oxford Biomedical Lt(OXBDF)

Description: Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Immune Design. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.


Keywords: Biopharmaceutical Life Sciences Biology Immunotherapy Partnership Cancer Immunotherapy Parkinson's Disease Cell Therapy Gene Therapy Medical Genetics Virotherapy Macular Degeneration Genetic Engineering Platform Technology Diabetic Retinopathy Fibrosis Central Nervous System Disorders Treatment Of Parkinson's Disease Retina Cystic Fibrosis Applied Genetics Retinopathy Gene Delivery Cell Therapy Products Imperial Treatment Of Various Cancers Bioprocess Bioprocessing Cyst Orchard Therapy Products Thk Oxb Stargardt Disease Vector Usher Syndrome Viral Vector Bioverativ Treatment Of Stargardt Disease

Home Page: www.oxb.com

Windrush Court
Oxford, OX4 6LT
United Kingdom
Phone: 44 1865 783 000


Officers

Name Title
Dr. Roch Doliveux Interim CEO & Chairman
Mr. Stuart Paynter CFO, Company Sec. & Director
Mr. Nick Page Chief Operations Officer
Dr. James Miskin Ph.D. Chief Technical Officer
Dr. Kyriacos Mitrophanous Ph.D. Chief Scientific Officer
Mr. Matthew Treagus Chief Information Officer
Sophia Bolhassan Head of Investor Relations
Ms. Natalie Louise Walter Gen. Counsel
Dr. Jason Slingsby MBA Chief Bus. & Corp. Devel. Officer
Ms. Sarah Macleod Head of Communications

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 232.5581
Trailing PE: 23.75
Price-to-Book MRQ: 1.6867
Price-to-Sales TTM: 3.5963
IPO Date:
Fiscal Year End: December
Full Time Employees: 959
Back to stocks